371,222 Shares in Kenvue Inc. $KVUE Bought by Kintayl Capital LP

Key Points

• Kintayl Capital LP acquired 371,222 Kenvue shares worth approximately $7.1 million, making KVUE its ninth-largest holding and representing 2.8% of its portfolio.
• Institutional ownership remains high at 97.64%, with major investors including BlackRock, Norges Bank, Independent Franchise Partners and Legal & General adding or initiating positions.
• Kenvue reported quarterly EPS of $0.31, slightly below estimates, while revenue rose 3% year over year. The company pays a $0.21 quarterly dividend, yielding about 4.3%, but analysts maintain a consensus “Hold” rating with a $19.27 price target.

Kintayl Capital LP bought a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 371,222 shares of the company's stock, valued at approximately $7,094,000. Kenvue accounts for about 2.8% of Kintayl Capital LP's investment portfolio, making the stock its 9th largest holding.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Kenvue in the second quarter worth approximately $2,882,279,000. Norges Bank purchased a new position in Kenvue during the fourth quarter valued at approximately $756,862,000. Independent Franchise Partners LLP grew its position in Kenvue by 56.3% during the fourth quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company's stock valued at $830,527,000 after purchasing an additional 17,343,785 shares in the last quarter. Legal & General Group Plc purchased a new position in Kenvue during the second quarter valued at approximately $253,393,000. Finally, Sculptor Capital LP increased its stake in Kenvue by 1,023.5% in the 4th quarter. Sculptor Capital LP now owns 12,886,328 shares of the company's stock valued at $222,289,000 after buying an additional 11,739,328 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $19.34 on Wednesday. The company has a market capitalization of $37.16 billion, a PE ratio of 22.24, a price-to-earnings-growth ratio of 1.39 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. Kenvue Inc. has a one year low of $14.02 and a one year high of $21.40. The company's fifty day moving average price is $19.10 and its 200 day moving average price is $18.22.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.01). The firm had revenue of $3.96 billion for the quarter, compared to the consensus estimate of $3.97 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm's revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the company earned $0.29 earnings per share. As a group, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Investors of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.3%. The ex-dividend date is Wednesday, August 12th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. Kenvue's dividend payout ratio is currently 96.55%.

Analysts Set New Price Targets

KVUE has been the subject of a number of research reports. Wall Street Zen lowered shares of Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Zacks Research downgraded shares of Kenvue from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Weiss Ratings upgraded Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a report on Monday, June 15th. UBS Group reduced their price objective on Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research report on Tuesday, August 11th. Finally, Barclays boosted their target price on Kenvue from $18.00 to $19.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company's stock. According to data from MarketBeat, Kenvue has a consensus rating of "Hold" and a consensus target price of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.